glp 1 seizures Top GLP-1 Agonists Balance Weight Loss Efficacy, Safety Association Between GLP-1 Receptor Agonist
Description
Food and Drug Administration (FDA) approved aducanumab as the first disease-modifying therapy (DMT) for AD in June 2021, 10 there has been considerable medical and scientific controversy regarding its curative effect
2 This pandemic of obesity has placed a substantial burden on healthcare systems and patients alike, sparking intense interest in the development of novel therapeutic strategies
It reduces body weight
This isnt upselling its risk management
A case report highlighted a patient on semaglutide exhibiting significant gastric content despite fasting, indicating the need for caution during anesthesia
Furthermore, their use in cardiovascular conditions is also being researched
